BioProcess International Conference & Exhibition

BioProcess International Conference

The BioProcess International conference and exhibition 2017, will be held September 25-28 at the Hynes Convention Center in  Boston Massachusetts, USA.
The conference is the largest exhibition devoted to biomanufacturing and brings you the science, technologies and partners needed to accelerate promising biologics towards commercial success.
We at Novo Nordisk Pharmatech  invite you to visit our both (both 927) to discover more about recombinant insulin for innovative biologics and pharmaceutical grade Quaternary ammonium compounds.

At Novo Nordisk Pharmatech we remain the  leading worldwide supplier of recombinant insulin. Our recombinant insulin is a key component in serum free growth media for mammalian cells and approved by regulatory bodies worldwide, including FDA and EMA, and our products are manufactured to cGMP standards, and we guarantee:

  • Global regulatory compliance
  • Consistent high quality
  • Extensive regulatory documentation
  • Continuous availability
  • Secure global supply chain
  • High levels of service and support

We deliver a proven record of product PurityReliability and Consistency and can even tailor Quality products for future therapies.


Increase viable CHO cell density in commercial available cell culture medium by supplementation with non-animal insulin

CHO cells are one of the most widely used platforms for the production of biopharmaceuticals. Increased demand for safety and reliability has moved the standard for CHO cell culture media from Serum containing to Serum free and further on to chemically defined media. UAB in collaboration with Novo Nordisk Pharmatech (world’s largest supplier of recombinant insulin) has shown that addition of animal origin free insulin to three leading commercially available off-the-shelf chemically defined media resulted in significant increases in viable cell density. In addition to this benefit insulin has been proven to aid in the expression of difficult to express proteins. Please stop by our booth for a talk how insulin could play an important role in your upstream process and for the chance to win an Amazon kindle.

Read More


Increase specific Influenza production with recombinant human insulin

The vaccine industry is challenged to produce large quantities of vaccines in a rapid and cost-effective way. Major changes to current bioprocesses are both difficult and very expensive to implement. Using HEK293 it has been demonstrated that addition of recombinant human insulin to commercially available chemically defined media, can be used as a supplement to increase VCD and specific viral yield.

*Data kindly supplied by Aziza Manceur, National Research Council Canada. Hemagglutinin (HA) assay is used for quantification of Influenza (H1N1). Insulin Human AF used in the experiments is supplied by Novo Nordisk Pharmatech. CD 293 media is trademark of Thermo Fisher Scientific.

Read More


 

If you want to learn more about our recombinant Insulin Human click here

We look forward to see you at our both to a talk about why you should grow your cells with insulin from Novo Nordisk Pharmatech A/S.

 


 

"The largest bioprocessing event bringing you the science, technologies and partners needed to accelerate promising biologics towards commercial success"

- http://www.bioprocessintl.com/

Contact

Vanessa León

Marketing Manager

Email

Direct phone: +45 4042 6284